Electronic Supplementary Material (ESI) for RSC Advances. This journal is © The Royal Society of Chemistry 2015

## **Supporting Information**

## Harmonized tuning of nucleic acid and lectin binding properties with multivalent cyclodextrins for macrophage-selective gene delivery

Alejandro Méndez-Ardoy, Alejandro Díaz-Moscoso, Carmen Ortiz Mellet, Christophe Di Giorgio,\* Pierre Vierling, Juan M. Benito\* and José M. García Fernández

## List of Contents:

- **S2 to S4** Synthesis of statistically mannosylated paCDs **1b-e** and **2b-e**.
- **S5 to S6** <sup>1</sup>H NMR spectra of paCDs **1b-e** and **2b-e** (Fig S1-S2).
- **S7 to S8** ESI-MS spectra of paCDs **1b-e** and **2b-e** (Fig S3-S10).
- S9 NaCl-induced variation of glycoCDplex hydrodynamic diameter and ζpotential (Fig S11).
- **S10** Ethidium bromide exclusion efficiency vs NaCl concentration (Fig. S12).
- **S11** Transfection efficiency in BNL-CL2, COS-7, and RAW 264.7 cells as compared to negative (naked pDNA) and positive (jetPEI polyplexes) controls (Fig S13).

## Synthesis.

Procedure for statistical mannosylation of paCD 1a.



To a solution of  $1a^1$  (50 mg, 12 µmol) and Et<sub>3</sub>N (47 µL, 0.34 mmol, 2 eq) in dry DMF (5 mL), a solution of 2-isothiocyanatoethyl  $\alpha$ -D-mannopyranoside  $3^2$  (2.2 mg, 6.7 mg, 13.3 mg or 22.3 mg for 0.05, 0.15, 0.30 or 0.50 eq per primary amino group, respectively) in DMF (5 mL) was added and the solution was stirred overnight at room temperature. The solvent was removed under vacuum and the residue was purified by exclusion chromatography (Sephadex G-25) using water as eluent. The purified compound was dissolved in diluted HCl 0.1 N and freeze-dried to give a white foam in nearly quantitative yields. <sup>1</sup>H NMR (500 MHz, D<sub>2</sub>O, 323 K)  $\delta$  8.60-8.40 (m, =CH), 5.80-5.60 (m, H-1<sub>CD</sub>, H-3<sub>CD</sub>), 5.30-5.00 (m, H-6<sub>CD</sub>), 5.00-4.50 (H-2<sub>CD</sub>, H-5<sub>CD</sub>, H-1<sub>man</sub>), 4.20-3.60 (CH<sub>2</sub>N<sub>triazole</sub>, H-4<sub>CD</sub>, H-2<sub>man</sub>, CH<sub>2</sub>O<sub>man</sub>, H-6<sub>man</sub>, H-3<sub>man</sub>, H-4<sub>man</sub>, H-5<sub>man</sub>), 3.50-2.90 (CH<sub>2</sub>NH<sub>thiourea</sub>, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>N), 2.70-2.30 (CH<sub>2</sub>-5 hexanoyl), 1.79 (CH<sub>2</sub>-4 hexanoyl), 1.50 (CH<sub>2</sub>-2,3 hexanoyl), 1.07 (CH<sub>3</sub> hexanoyl).

ESI-MS for **1b** (5% mannosylation extent): *m/z* unmannosylated: 735.6 [M + 5 H]<sup>5+</sup>, 918.8 [M + 4 H]<sup>4+</sup>, 1225 [M + 3 H]<sup>3+</sup>; mono-mannosylated: 985.3 [M + 4 H]<sup>4+</sup>, 1313.4 [M + 3 H]<sup>3+</sup>; di-mannosylated: 1051.8 [M + 4 H]<sup>4+</sup>.

ESI-MS for **1c** (15% mannosylation extent): *m/z* unmannosylated: 735.4 [M+ 5 H]<sup>5+</sup>; dimannosylated: 1051.3 [M + 4 H]<sup>4+</sup>, 1401.7 [M + 3 H]<sup>3+</sup>; tri-mannosylated: 1118.1 [M + 4 H]<sup>4+</sup>, 1490.1 [M+ 3 H]<sup>3+</sup>.

ESI-MS for **1d** (30% mannosylation extent): m/z di-mannosylated: 1051 [M + 4 H]<sup>4+</sup>, 1400.2  $M_{\rm e} = 1000$  M  $M_{\rm e} = 1$ 

<sup>2</sup> C. Grabosch, K. Kolbe and T. K. Lindhorst, *ChemBioChem*, 2012, **13**, 1874.

tetra-mannosylated: 946.9 [M + 5 H]<sup>5+</sup>, 1183.1 [M + 4 H]<sup>4+</sup>, 1577 [M + 3 H]<sup>3+</sup>; penta-mannosylated: m/z 1249.6 [M + 4 H]<sup>4+</sup>, 1664.8 [M + 3 H]<sup>3+</sup>.

ESI-MS for **1e** (50% mannosylation extent): *m/z* hexa-mannosylated: 1053.9 [M + 5 H]<sup>5+</sup>, 1316.6 [M + 4 H]<sup>4+</sup>, 1755.0 [M + 3 H]<sup>3+</sup>; hepta-mannosylated: 1106.9 [M + 5 H]<sup>5+</sup>, 1382.9 [M + 4 H]<sup>4+</sup>; octa-mannosylated: 1159 [M + 5 H]<sup>5+</sup>, 1449.4 [M + 4 H]<sup>4+</sup>; nona-mannosylated: 1515.9 [M + 4 H]<sup>4+</sup>.

Procedure for statistical mannosylation of paCD 2a.



To a solution of  $2a^3$  (50 mg, 10.5 µmol) and Et<sub>3</sub>N (40 µL, 0.29 µmol, 2 eq) in dry DMF (4 mL), a solution of 2-isothiocyanatoethyl  $\alpha$ -D-mannopyranoside  $3^2$  (1.96, 5.88, 11.72 or 19.52 mg for 0.05, 0.15, 0.30 or 0.50 eq per primary amino group, respectively) in DMF (5 mL) was added and the solution was stirred overnight at room temperature. The solvent was removed under vacuum and the residue was purified by exclusion chromatography (Sephadex G-25) using water as eluent. The purified compound was dissolved in diluted HCl 0.1 N and freeze-dried to give a white foam in nearly quantitative yield. Yield: 48.2, 48.6, 42.2 and 40.0 mg respectively (93, 87, 68 and 58%). <sup>1</sup>H NMR (500 MHz, 5:1 MeOD-D<sub>2</sub>O, 313 K)  $\delta$  5.35 (nm, H-3<sub>CD</sub>), 5.19 (m, H-1<sub>CD</sub>), 4.87 (m, H-2<sub>CD</sub>, H-1<sub>man</sub>), 4.20 (m, H-5<sub>CD</sub>), 4.06 (CH<sub>2</sub>O<sub>man</sub>), 3.96 (m, H-4<sub>CD</sub>), 3.94 (m, H-2<sub>man</sub>), 3.83-3.68 (CH<sub>2</sub>NH<sub>thiourea</sub>, H-3-5<sub>man</sub>), 3.60 (m, CH<sub>2</sub>N<sub>man</sub>), 3.22 (CH<sub>2</sub>NH<sub>2</sub>), 3.00 (m, CH<sub>2</sub>N), 2.95-2.88 (m, H-6<sub>CD</sub>, CH<sub>2</sub>S), 2.48-2.24 (CH<sub>2</sub>-5 hexanoyl), 1.65 (CH<sub>2</sub>-4 hexanoyl), 1.38 (CH<sub>2</sub>-2,3 hexanoyl), 0.94 (CH<sub>3</sub> hexanoyl).

ESI-MS for **2b** (5% mannosylation extent): *m/z* unmannosylated: 1060.9 [M + 4 H]<sup>4+</sup>, 1414.1 [M + 3 H]<sup>3+</sup>, 2121.1 [M + 2 H]<sup>2+</sup>; mono-mannosylated: 1127.3 [M + 4 H]<sup>4+</sup>, 1502.8 [M + 3H]<sup>3+</sup>, 2253.6 [M + 2 H]<sup>2+</sup>; di-mannosylated: 1194.1 [M + 4 H]<sup>4+</sup>, 1590.8 [M + 3 H]<sup>3+</sup>.

<sup>&</sup>lt;sup>3</sup> A. Díaz-Moscoso, L. Le Gourrierec, M. Gómez-García, J. M. Benito, P. Balbuena, F. Ortega-Caballero, N. Guilloteau, C. Di Giorgio, P. Vierling, J. Defaye, C. Ortiz Mellet and J. M. García Fernández, *Chem. – Eur. J.*, 2009, **15**, 12871.

ESI-MS for **2c** (15% mannosylation extent): *m/z* unmannosylated: 1061.0 [M + 4H]<sup>4+</sup>, 1414.3 [M + 3 H]<sup>3+</sup>; mono-mannosylated: 1127.9 [M + 4 H]<sup>4+</sup>, 1502.5 [M + 3 H]<sup>3+</sup>, 2254.0 [M + 2 H]<sup>2+</sup>; di-mannosylated: 1194.1 [M + 4 H]<sup>4+</sup>, 1591.1 [M + 3 H]<sup>3+</sup>, 2385.5 [M + 2 H]<sup>2+</sup>; tri-mannosylated: 1260.0 [M + 4 H]<sup>4+</sup>, 1679.5 [M + 3 H]<sup>3+</sup>.

ESI-MS for **2d** (30% mannosylation extent): *m/z* di-mannosylated: 955.1 [M + 5 H]<sup>5+</sup>, 1193.5 [M + 4 H]<sup>4+</sup>, 1591.0 [M + 3 H]<sup>3+</sup>; tri-mannosylated: 1008.1 [M + 5 H]<sup>5+</sup>, 1259.7 [M + 4 H]<sup>4+</sup>, 1679.0 [M + 3 H]<sup>3+</sup>; tetra-mannosylated: 1061.0 [M + 5 H]<sup>5+</sup>, 1326.5 [M + 4 H]<sup>4+</sup>, 1768.5 [M + 3 H]<sup>3+</sup>; penta-mannosylated: 1392.7 [M + 4 H]<sup>4+</sup>,1857.0 [M + 3 H]<sup>3+</sup>.

ESI-MS for **2e** (50% mannosylation extent): *m/z* di-mannosylated: 1193.9 [M + 4 H]<sup>4+</sup>, 1581.0 [M + 3 H]<sup>3+</sup>; tri-mannosylated: 1259.6 [M + 4 H]<sup>4+</sup>, 1679.0 [M + 3 H]<sup>3+</sup>; tetra-mannosylated: 1326.5 [M + 4 H]<sup>4+</sup>, 1768.5 [M + 3 H]<sup>3+</sup>; penta-mannosylated: 1392.5 [M + 4 H]<sup>4+</sup>, 1857.0 [M + 3 H]<sup>3+</sup>; octa-mannosylated: 1061.5 [M + 6 H]<sup>6+</sup>, nona-mannosylated: 1326.4 [M + 5 H]<sup>5+</sup>.



**Figure S1**. <sup>1</sup>H NMR (500 MHz, D<sub>2</sub>O, 323 K) spectra of statistically mannosylated paCDs **1b-e** with indication of the relative CD/Man amount resulting from the integration of  $CH_2N$  vs  $CH_2N_{man}$  signals.



**Figure S2**. <sup>1</sup>H NMR (500 MHz, 5:1 MeOD-D<sub>2</sub>O, 313 K) spectra of statistically mannosylated paCDs **2b-e** with indication of the relative CD/Man amount resulting from the integration of H-5<sub>CD</sub> vs [H- $2_{CD}$  + H- $1_{man}$ ] signals.



Figure S3. ESI-MS spectrum of 1b.



Figure S4. ESI-MS spectrum of 1c.



Figure S5. ESI-MS spectrum of 1d.



Figure S6. ESI-MS spectrum of 1e.







Figure S8. ESI-MS spectrum of 2c.



Figure S9. ESI-MS spectrum of 2d.



Figure S10. ESI-MS spectrum of 2e.



**Figure S11**. Hydrodynamic diameter of CDplexes (N/P 7) formulated in the absence (white bars) or in the presence of NaCl (50 or 150 mM, dotted and slashed bars, respectively) with paCD **1a** and **2a**, and their corresponding statistically mannosylated derivatives **1b-e** and **2b-e** (top and bottom panels, respectively).



**Figure S12**. Ethidium bromide exclusion efficiency vs saline concentration of CDplexes (N/P ratio 7) formulated with paCD **1a** and **2a**, and their corresponding statistically mannosylated derivatives (top and bottom panels, respectively). To investigate pDNA release, the fluorescence intensity due to ethidium bromide intercalation was monitored at increasing concentration of NaCl. The ease of pDNA release is correlated with Man content, thus at 250 mM NaCl, ethidium bromide intercalation efficiency in **1e** was twice that of **1a**.



**Figure S13**. Transfection efficiency in terms of luciferase expression in BNL-CL2, COS-7, and RAW 264.7 cells for CDplexes formulated at N/P 5 with triazol-tethered (**1a**, grey bars; **1c**, dotted bars; **1d**, slashed bars; panel A) and thiourea-tethered (**2a**, grey bars; **2c**, dotted bars; **2d**, slashed bars; panel B) paCDs. Naked pDNA and jetPEI polyplexes (formulated at their optimal N/P 10) were used as negative and positive controls, respectively.